AB
AQST icon

Amalgamated Bank’s Aquestive Therapeutics AQST Stock Holding History

Amalgamated Bank’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,282
Closed -$21K – 1697
2025
Q4 		$21K Buy
3,282
+713
+28% +$4.44K ﹤0.01% 2082
2025
Q3 		$14K Hold
2,569
– – ﹤0.01% 2286
2025
Q2 		$9K Hold
2,569
– – ﹤0.01% 2459
2025
Q1 		$7K Hold
2,569
– – ﹤0.01% 2511
2024
Q4 		$9K Hold
2,569
– – ﹤0.01% 2462
2024
Q3 		$13K Hold
2,569
– – ﹤0.01% 2309
2024
Q2 		$7K Buy
+2,569
New +$8.58K ﹤0.01% 2593

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Amalgamated Bank's AQST Position: Q1 2026 in Review

Amalgamated Bank sold out of Aquestive Therapeutics (AQST) in Q1 2026, closing a stake of 3,282 shares — an estimated $21K sold.

Amalgamated Bank first reported a position in AQST in Q2 2024 and held it in 7 quarters. The position peaked at $21K in Q4 2025. 180 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Amalgamated Bank reported no remaining Aquestive Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 3,282 Aquestive Therapeutics shares in Q1 2026, an estimated $21K.
  • Amalgamated Bank first reported a position in Aquestive Therapeutics in Q2 2024 and held it in 7 quarters.
  • Amalgamated Bank's Aquestive Therapeutics position peaked at $21K in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.